Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab as adjuvant therapy in completely resected stage II–IIIB NSCLC
2017-004011-39Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Canakinumab adjuvant arm with Placebo arm (2 arms). Primary endpoint: Disease-free survival (DFS). Started Dec 2017; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-004011-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004011-39.